BDX DEF 14A: Executive Compensation & Equity Awards Detailed

Ticker: BDX · Form: DEF 14A · Filed: Dec 19, 2024 · CIK: 10795

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance

Related Tickers: BDX

TL;DR

BDX dropped its proxy statement detailing exec pay & equity awards for FY24. Check it for comp details.

AI Summary

Becton Dickinson & Co. (BDX) filed its DEF 14A on December 19, 2024, detailing executive compensation and corporate governance for the fiscal year ending September 30, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-PEO named executive officers, with specific details on the value of outstanding and unvested equity awards as of September 30, 2024.

Why It Matters

This filing provides transparency into how Becton Dickinson compensates its top executives, which can influence investor perception and proxy voting decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing providing information on executive compensation and corporate governance, not indicating new financial risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, including the election of directors, executive compensation, and other corporate actions.

When did Becton Dickinson & Co. file this DEF 14A?

Becton Dickinson & Co. filed this DEF 14A on December 19, 2024.

What fiscal year does this filing primarily cover?

This filing primarily covers the fiscal year ending on September 30, 2024.

What type of compensation information is detailed in this filing?

The filing details executive compensation, including information on equity awards granted to principal executive officers (PEO) and non-PEO named executive officers, and the value of outstanding and unvested equity awards.

Where is Becton Dickinson & Co. headquartered?

Becton Dickinson & Co. is headquartered in Franklin Lakes, New Jersey.

Filing Stats: 4,362 words · 17 min read · ~15 pages · Grade level 14.7 · Accepted 2024-12-19 10:36:53

Key Financial Figures

Filing Documents

From the Filing

bdx-20241219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Becton, Dickinson and Company (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, New Jersey 07417-1880 www.bd.com December 19, 2024 Dear fellow shareholders: Across the healthcare ecosystem, seismic shifts in technology and care models are revolutionizing patient care. The industry faces unprecedented change, from rising costs to clinician shortages to increasing patient complexities and the location of care delivery. At BD, we have built a company that is enabling the healthcare of today, while helping our customers create the healthcare of tomorrow and succeed in this complex landscape. In FY24, our teams delivered strong execution on our BD 2025 strategy to grow through leading innovations, expand margins through simplification and operational excellence, and build an agile, empowered team that is bringing our strategy to life. Our innovative portfolio is positioned at the forefront of significant trends reshaping healthcare. We are combining AI, robotics, and informatics with deep customer and patient insights to deliver connected, intelligent solutions that improve the cost and quality of the core processes underlying care delivery around the world. Today, we have a $4 billion connected care portfolio and are advancing our leadership in intelligent medication management, and pharmacy and microbiology robotics. Our acquisition of Edwards Lifesciences' Critical Care business has expanded our portfolio of connected care solutions with leading advanced patient monitoring technologies, including advanced AI algorithms and clinical decision support tools. Our innovations are enabling care to be delivered in new settings, helping patients manage conditions at home – such as urinary incontinence with our PureWick franchise – and enabling delivery of life-changing biologic drugs through our prefillable syringes like the BD Neopak and BD Vystra self-injection devices. As the global leader in biologics drug delivery, with unmatched innovations and capacity, BD is ideally positioned to be the partner of choice and capitalize on this significant growth potential. We continue to make great strides improving outcomes for those living with chronic disease. BD innovations, such as our BD FACSDiscover S8 Cell Sorters, are enabling new insights into the human immune system and contributing to breakthroughs in cell and immune oncology therapies. The BD COR System and BD Onclarity HPV assay are helping to transform and expand cancer screening around the world by enabling women to self-sample at home for the virus strains that cause cervical cancer. Our impact continues through enabling advanced tissue repair and reconstruction with our resorbable mesh portfolio, comprised of Phasix and GalaFLEX. We have built a strong innovation pipeline and are on track to meet our BD 2025 goal of launching 100 new products by the end of 2025. As we help to reshape the future of healthcare, our customers continue to rely on our more than 38 billion devices every year that deliver the healthcare of today across more than 190 countries. To fuel investments in innovation and support our customers in transforming care delivery, we have accelerated the simplification of our company and our focus on operational excellence – visible in our strong FY24 progress in margins, EPS and cash flow. Enabling this is our BD Excellence business system, which is being embedded throughout our company. We completed over 500 Kaizen events this year, improving quality and safety, reducing waste and delivering meaningful savings. We increased operating efficiency across our top 150 production lines by 20%, enabling more efficient use of capital. While we are in early stages, we have seen significant results in manufacturing and are expanding BD Excellence into commercial, R&D and other areas of the company. 2025 Notice of Annual Meeting and Proxy Statement 1 Excellence is also fundamental to how we approach corporate sustainability. We are exceeding the sustainability goals we set in 2021 and are on track to meet our 2030 emission reduction goals. Notably, we reduced Scope 1 and 2 GHG emiss

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing